My research program is focused on the identification of genetic and epigenetic markers for cancer prevention, progression as well as drug response. The laboratory is a humid laboratory, combining both wet-lab techniques and bioinformatics analysis to study cancer samples from patients and animal models of cancer. I have more than 18 years of experience generating and analyzing genomic data from chromatin, transcriptome, and resequencing projects, applying them to translational cancer research for the past 10 years. I evaluated the different Next Generation Sequencing technologies for their use in targeted sequencing to identify human DNA variants, both generating the data and performing the bioinformatics analysis. I have also played a key role in the development of targeted sequencing methods such as exome sequencing. I applied these technologies to profile the mutational landscape of glioblastoma, appendix cancer, mesothelioma, gastro-intestinal stromal tumors and leukemia, as well as to support clinical diagnostics through the development of the Ultra Deep targeted sequencing (UDT-Seq) assay. My current research focuses on the identification of biomarkers and therapeutic targets for 1) carboplatin resistance in ovarian cancer, and 2) progression of pre-malignant lesions in Oral squamous Cell carcinoma (M4O-prevent trial) and breast cancer (Molecular and Cellular Lesion - NCI Consortium), both using combinations of bulk and single cell molecular profiling associated with multidimensional reduction methods. I lead several data stewardship efforts: implementation of clinical genetics data sharing, reporting and analytics for the cancer center biorepository, and construction of the breast DCIS registry.